Liver Diseases  >>  ribavirin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

58 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ribavirin / Generic mfg.
480S, NCT00953589 / 2009-011182-86: 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)

Completed
2b
74
Europe, RoW
ribavirin, Ribasphere
Biolex Therapeutics, Inc.
Hepatitis C, Chronic
05/10
01/11
NCT00959699 / 2008-004864-38: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

Checkmark
Jun 2013 - Jun 2013: 
Completed
2b
99
NA
PegIFN-2b, SCH 054031, MK-4031, Pegylated interferon alfa-2b, Peginterferon alfa-2b, RBV, Ribavirin, Placebo to Boceprevir, Boceprevir, SCH 503034, MK-3034, Victrelis
Merck Sharp & Dohme LLC
HIV Infections, Hepatitis C, HCV Infection
05/12
10/12
NCT01215643 / 2010-020034-26: Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Checkmark VITAL-1 - APASL 2013
Jun 2013 - Jun 2013: VITAL-1 - APASL 2013
Checkmark VITAL-1 - APASL 2013
Jun 2013 - Jun 2013: VITAL-1 - APASL 2013
Checkmark VITAL-1 - APASL 2013
More
Completed
2b
340
US, Canada, Europe, RoW
Alisporivir, DEB025, ALV, Peginterferon alfa-2a, Pegasys®, PEG, Ribavirin, Copegus®, RBV
Debiopharm International SA
Hepatitis C, Chronic Pain
05/12
05/12
NCT01581138: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Completed
2b
64
US
VX-222, telaprevir, VX-950, INCIVEK, INCIVO, TELAVIC, ribavirin, Copegus
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
06/13
12/13
D-LITE, NCT01795911: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed
2b
165
US
Pegylated Interferon Lambda, BMS-914143, Ribasphere, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
04/14
09/14
D-LITE, NCT01309932 / 2010-022568-11: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE
More
Completed
2b
165
Japan, US, Europe, RoW
Pegylated Interferon Lambda (pegIFNλ), BMS-914143, BMS-790052 (NS5A Inhibitor), BMS-790052, Ribavirin (RBV), Ribasphere, BMS-650032 (NS3 Protease Inhibitor), BMS-650032, Pegylated Interferon Alfa-2a (pegIFNα-2a), Pegasys®, Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo for BMS-650032, Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for BMS-790052, Placebo for Ribavirin (RBV), Placebo for Ribasphere
Bristol-Myers Squibb
Hepatitis C
07/14
09/14
NCT01830127 / 2012-003534-17: BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Completed
2b
35
US, Europe
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Boehringer Ingelheim
Hepatitis C, Chronic
10/14
10/14
NCT02120300: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Completed
2b
122
US
LDV/SOF, Harvoni®, GS-5885/GS-7977, SOF, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Chronic HCV Infection
08/15
08/15
NCT01017575: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Completed
2a
55
Japan
Daclatasvir, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Infection
10/11
10/11
NCT01265511: Study of SCY-635, Pegasys and Copegus in Hepatitis C

Completed
2a
10
US
Placebo, Batch # BMR/10/731, SCY-635, Pegasys, Copegus
Scynexis, Inc.
Hepatitis C Infection
10/11
10/11
NCT01849562: Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Checkmark Highlights of Clinical Results
Feb 2015 - Feb 2015: Highlights of Clinical Results
Checkmark For ACH-3102 + RBV Phase 2a-005 trial for hep C infection
Jun 2014 - Jun 2014: For ACH-3102 + RBV Phase 2a-005 trial for hep C infection
Checkmark ACH-3102 + sovaprevir + RBV trial for hep C infection
More
Completed
2a
30
NA
Sovaprevir, ACH-0141625, ACH-3102, Ribavirin, Placebo
Alexion, Achillion, a wholly owned subsidiary of Alexion
Hepatitis C, Chronic
11/13
04/14
NCT01859962: Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark HepDART 2013
Dec 2013 - Dec 2013: HepDART 2013
Checkmark AASLD 2013
More
Completed
2a
38
US
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Presidio Pharmaceuticals, Inc., Boehringer Ingelheim
Chronic Hepatitis C
05/14
12/14
NCT01790100: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Completed
2a
20
RoW
VX-135, Ribavirin
Alios Biopharma Inc., Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
06/14
06/14
NCT00031343: The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

Completed
2
128
US
highly active antiretroviral therapy (HAART)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
 
04/04
NCT00502788 / 2008-002209-38: Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

Completed
2
21
US, Canada, Europe
Peginterferon Alfa-2a and Ribavirin, Human recombinant E. Coli, Hoffmann-la Roche, Ribavirin
HealthCore-NERI, National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis C, Thalassemia
06/06
08/06
NCT00277238: CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Completed
2
113
US
CPG10101, Control
Pfizer
Hepatitis, Chronic Active
07/07
07/07
NCT00292084: An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

Completed
2
60
Canada
Celgosivir
BioWest Therapeutics Inc
Hepatitis C, Chronic
 
10/07
NCT00395421: Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Completed
2
114
US
NM283 plus Peg-IFNα-2a
Merck Sharp & Dohme LLC, Novartis Pharmaceuticals
Chronic Hepatitis C
06/08
08/08
PIFNPK, NCT00085917: Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Completed
2
29
US
Double dose pegylated interferon with weight based Ribavirin, Pegasys, standard dose pegylated interferon alfa -2a and ribavirin, pegasys
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
11/08
11/08
NCT00517439 / 2006-006604-11: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Checkmark P2 data
Dec 2011 - Dec 2011: P2 data
Completed
2
516
US, Canada, Europe, RoW
Copegus, Pegasys, RO4588161
Hoffmann-La Roche
Hepatitis C, Chronic
01/10
01/10
NCT00944684: High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Completed
2
32
Europe
High ribavirin dose, Standard ribavirin dose
University of Bern, Roche Pharma AG, University of Lausanne, Cantonal Hospital of St. Gallen, Waid City Hospital, Zurich, University of Basel
Chronic Hepatitis C
04/11
04/11
NCT00774397 / 2008-003538-11: Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Checkmark SILEN-C1; EASL 2012
Apr 2012 - Apr 2012: SILEN-C1; EASL 2012
Checkmark SILEN-C1
Apr 2011 - Apr 2011: SILEN-C1
Completed
2
719
US, Canada, Europe, RoW
BI 201335 NA 240 mg QD / LI, Faldaprevir, PegIFN/RBV, BI 201335 NA 120mg QD / LI, BI 201335 NA 240 mg QD, BI 201335 NA 240 mg BID, Placebo
Boehringer Ingelheim
Hepatitis C, Chronic
11/11
 
NCT00963885 / 2009-009608-38: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Checkmark
Jul 2013 - Jul 2013: 
Checkmark AASLD 2011: ATLAS
Oct 2011 - Oct 2011: AASLD 2011: ATLAS
Completed
2
229
US, Canada, Europe, RoW
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Hoffmann-La Roche
Hepatitis C, Chronic
01/12
01/12
NCT00987337 / 2009-009214-40: Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Completed
2
288
US, Canada, Europe, RoW
Filibuvir, Placebo
Pfizer
Hepatitis, Hepatitis C
01/12
01/12
NCT00869661 / 2008-008258-21: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Checkmark PROPEL & JUMP-C
Mar 2014 - Mar 2014: PROPEL & JUMP-C
Checkmark EASL data
Apr 2012 - Apr 2012: EASL data
Completed
2
413
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048
Hoffmann-La Roche
Hepatitis C, Chronic
02/12
02/12
ETOC, NCT00901524 / 2008-000859-10: ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV

Checkmark EASL 2013: ANRS-HC-20 ETOC
Apr 2013 - Apr 2013: EASL 2013: ANRS-HC-20 ETOC
Checkmark P2 AASLD (peginterferon 2a+2b)
Oct 2012 - Oct 2012: P2 AASLD (peginterferon 2a+2b)
Completed
2
58
Europe
Peg-interféron alpha 2a + ribavirin
ANRS, Emerging Infectious Diseases, Roche Pharma AG
Hepatitis
06/12
06/12
NCT01331850 / 2010-019585-90: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Checkmark MATTERHORN
Sep 2014 - Sep 2014: MATTERHORN
Checkmark AASLD 2012: MATTERHORN
Oct 2012 - Oct 2012: AASLD 2012: MATTERHORN
Completed
2
381
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
01/13
01/13
NCT01359644: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Checkmark ACG 2014
Sep 2014 - Sep 2014: ACG 2014
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark EASL 2014
More
Completed
2
350
US
PSI-7977, Daclatasvir, BMS-790052, Ribavirin, Copegus ®
Bristol-Myers Squibb, Pharmasset
Chronic Hepatitis C
01/13
10/13
NCT01435226 / 2011-002748-28: GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Completed
2
170
US, Europe
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Gilead Sciences
Hepatitis C, Chronic
01/13
07/13
QUANTUM, NCT01435044: Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

Checkmark EASL 2013: QUANTUM
Apr 2013 - Apr 2013: EASL 2013: QUANTUM
Checkmark QUANTUM
Apr 2012 - Apr 2012: QUANTUM
Completed
2
239
US
Sofosbuvir, Sovaldi™, GS-7977, PSI-7977, GS-0938, PSI-352938, RBV, Ribasphere®, Placebo to match sofosbuvir, Placebo to match GS-0938
Gilead Sciences, Quintiles, Inc.
Hepatitis C, Chronic
04/13
05/13
NCT01183169 / 2010-020033-14: Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Checkmark APASL 2014: FUNDAMENTAL
Mar 2014 - Mar 2014: APASL 2014: FUNDAMENTAL
Checkmark FUNDAMENTAL - APASL 2013
Jun 2013 - Jun 2013: FUNDAMENTAL - APASL 2013
Completed
2
459
US, Europe, RoW
Alisporivir, DEB025, ALV, Peginterferon alfa-2a, Pegasys®, PEG, Ribavirin, Copegus®, RBV, Placebo, ALV Placebo
Debiopharm International SA
Hepatitis C
05/13
05/13
NCT01726517: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Checkmark APASL 2014: LONESTAR
Mar 2014 - Mar 2014: APASL 2014: LONESTAR
Checkmark HepDART 2013: LONESTAR & ELECTRON
Dec 2013 - Dec 2013: HepDART 2013: LONESTAR & ELECTRON
Checkmark LONESTAR
More
Completed
2
100
US
LDV/SOF, Harvoni®, RBV
Gilead Sciences
Chronic Hepatitis C Virus
07/13
01/14
NCT01908335: A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Completed
2
212
RoW
PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis C
08/13
07/14
NCT01483742 / 2011-004129-28: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed
2
43
US, Canada, Europe, RoW
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
09/13
09/13
ANNAPURNA, NCT01628094 / 2012-000638-21: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Checkmark APASL 2014: ANNAPURNA
Mar 2014 - Mar 2014: APASL 2014: ANNAPURNA
Checkmark AASLD 2013: ANNAPURNA
Oct 2013 - Oct 2013: AASLD 2013: ANNAPURNA
Completed
2
110
US, Europe, RoW
RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
11/13
11/13
NCT01713283: Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Checkmark EASL 2014
Apr 2014 - Apr 2014: EASL 2014
Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark AASLD 2013
More
Completed
2
60
US
SOF, GS-7977, PSI-7977, Sovaldi®, RBV
Gilead Sciences
Hepatitis C Virus
11/13
02/14
NCT01687270 / 2012-002417-19: Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Checkmark
Oct 2014 - Oct 2014: 
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark APASL 2014
More
Completed
2
40
US, Europe, RoW
Sofosbuvir, GS-7977, PSI-7977, Sovaldi®, RBV, Ribasphere®
Gilead Sciences
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
12/13
08/14
NCT01911845: An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Completed
2
38
NA
ABT-450/r/ABT-267, ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir, ABT-333, dasabuvir, Ribavirin (RBV)
AbbVie
Chronic Hepatitis C Infection, Chronic Hepatitis C
12/13
09/14
NCT01726946: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Completed
2
10
US
VX-135, ribavirin
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
02/14
02/14
NCT01579019: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn
2
0
US
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
03/14
03/14
NCT01455090: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark CROI 2014
More
Completed
2
320
US, Europe
BMS-650032, Asunaprevir (ASV), BMS-790052, Daclatasvir (DCV), BMS-791325, Ribavirin, Copegus®
Bristol-Myers Squibb
Chronic Hepatitis C
03/14
07/15
NCT01559844 / 2012-000637-39: Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Checkmark
Sep 2014 - Sep 2014: 
Checkmark CDDW 2014
Dec 2013 - Dec 2013: CDDW 2014
Checkmark AASLD 2013
More
Completed
2
61
US, Europe, RoW
Sofosbuvir, GS-7977, PSI-7977, Sovaldi®, Ribavirin
Gilead Sciences
Hepatitis C, Hepatocellular Carcinoma
05/14
10/14
GS-US-342-0102, NCT01858766: Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark
More
Completed
2
379
US
SOF, GS-7977, PSI-7977, Sovaldi®, VEL, GS-5816, RBV, Ribasphere®
Gilead Sciences
Hepatitis C
05/14
08/14
GS-US-342-0109, NCT01909804: Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Completed
2
323
US, RoW
SOF, Sovaldi®, GS-7977, PSI-7977, VEL, GS-5816, RBV, Ribasphere®
Gilead Sciences
Hepatitis C
05/14
08/14
NCT01132313 / 2009-018197-66: Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Checkmark SOUND-C3
Sep 2014 - Sep 2014: SOUND-C3
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark APASL 2014: SOUND-C2 & SOUND-C3
More
Completed
2
488
US, Europe, RoW
BI 207127, BI 201335, Ribavirin, BI 207217
Boehringer Ingelheim
Hepatitis C, Chronic
10/14
10/14
NCT01687257 / 2012-002457-29: Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Checkmark AASLD 2015
Oct 2015 - Oct 2015: AASLD 2015
Completed
2
50
US, Europe, RoW
SOF, Sovaldi®, GS-7977, RBV
Gilead Sciences
Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
01/15
10/15
NCT01938430: Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Checkmark DDW 2016 (SOLAR1 and SOLAR 2)
Apr 2016 - Apr 2016: DDW 2016 (SOLAR1 and SOLAR 2)
Checkmark ILC 2016 (SOLAR1 and SOLAR 2)
Mar 2016 - Mar 2016: ILC 2016 (SOLAR1 and SOLAR 2)
Checkmark ILC 2015
More
Completed
2
339
US
LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV
Gilead Sciences
Chronic HCV Infection
01/15
03/15
NCT01749150: A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Completed
2
61
RoW
danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
02/15
02/15
NCT02068222: A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Completed
2
10
NA
ABT-450/ritonavir (r), ABT-450 also known as paritaprevir, ABT-530, pibrentasvir, Ribavirin (RBV)
AbbVie
Chronic Hepatitis C, Hepatitis C Virus
03/15
03/15
ALtitude II, NCT02094443 / 2013-003751-38: Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Completed
2
52
US, Europe
Alisporivir, DEB025, Ribavirin, Copegus®
Debiopharm International SA
Hepatitis C, Liver Disease
04/15
04/15
NCT02010255 / 2013-002802-30: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Checkmark DDW 2016 (SOLAR1 and SOLAR 2)
Apr 2016 - Apr 2016: DDW 2016 (SOLAR1 and SOLAR 2)
Checkmark ILC 2016 (SOLAR1 and SOLAR 2)
Mar 2016 - Mar 2016: ILC 2016 (SOLAR1 and SOLAR 2)
Checkmark DDW 2015
More
Completed
2
334
Canada, Europe, RoW
LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV
Gilead Sciences
Chronic HCV Infection
05/15
08/15
DAHHS, NCT01912495: Dutch Acute HCV in HIV Study

Checkmark DAHHS
Jun 2014 - Jun 2014: DAHHS
Completed
2
65
Europe
Boceprevir, Victrelis
Erasmus Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Onze Lieve Vrouwe Gasthuis, UMC Utrecht, University Medical Center Groningen, Maastricht University Medical Center, Rijnstate Hospital, Slotervaart Hospital, Radboud University Medical Center
Hepatitis C, Human Immunodeficiency Virus
08/15
01/16
NCT02300103: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Completed
2
69
US, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV
Gilead Sciences
Hepatitis C Virus Infection
07/16
09/16
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients

Recruiting
2
148
RoW
JKB-122, Placebo
Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd
Chronic Hepatitis C
08/16
 
CORAL-I, NCT01782495 / 2012-004792-39: A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Checkmark AASLD 2014 - CORAL-I
Nov 2014 - Nov 2014: AASLD 2014 - CORAL-I
Checkmark Presented at AASLD 2014 for HCV infection
Nov 2014 - Nov 2014: Presented at AASLD 2014 for HCV infection
Checkmark AVHC 2014
More
Completed
2
129
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, TECHNIVIE, ribavirin
AbbVie
Chronic Hepatitis C Infection
11/16
07/17
NCT01194037: A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Completed
1b/2a
30
US
recombinant variant of interferon-alpha 2b, Hanferon, Peginterferon alfa-2a, Pegasys
HanAll BioPharma Co., Ltd.
Chronic Hepatitis C Infection, Genotype 1
05/12
06/12
NCT01441180: GS-7977 With Ribavirin for Hepatitis C (SPARE)

Checkmark AASLD 2014: SPARE
Oct 2014 - Oct 2014: AASLD 2014: SPARE
Checkmark
Jul 2014 - Jul 2014: 
Checkmark CROI 2014: SYNERGY & SPARE
More
Completed
1/2
60
US
GS7977, sofosbuvir, RBV, ribasphere, ribapak
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
03/13
07/14
NCT01433133: Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients

Terminated
1/2
3
RoW
implantation
Medgenics Medical Israel Ltd.
Hepatitis C
10/13
03/14

Download Options